Decentralized clinical trial firm Curebase raised $40 million in a Sequence B spherical led by Business Ventures.
Acrew Capital, World Innovation Lab, Constructive Sum, Gaingels, GGV Capital, Daring Capital and Xfund participated within the funding, which additionally included a strategic funding from pharma large Gilead Sciences. The spherical brings Curebase’s complete increase to $59 million.
WHAT IT DOES
Curebase gives software program and operations help for managing decentralized clinical trials. That features an app for sufferers to allow them to discover and enroll in trials, signal consent types, entry telemedicine and schedule dwelling visits. The corporate additionally gives a site-facing platform to help with recruitment, prescreening potential individuals and managing their clinical trials.
Exterior of software program, Curebase staffers like principal investigators, analysis coordinators and venture managers may also help execute clinical trials by discovering potential websites, coaching and organising software program, and recruiting and retaining sufferers.
“Your conventional clinical trial takes place at a giant hospital, it is restricted to on-site participation. And that may result in sluggish recruitment of sufferers, lack of range and a much less satisfying affected person expertise, which in the end brings medicine and gadgets to market extra slowly,” Curebase founder and CEO Tom Lemberg informed MobiHealthNews.
“So we take the trial to the affected person. And our imaginative and prescient is actually to allow any affected person to be in a clinical trial, wherever they dwell, at dwelling and with their very own physician in their very own neighborhood.”
WHAT IT’S FOR
The startup plans to make use of the capital to spend money on its platform, together with by rising their design staff to enhance the person expertise for sufferers. Curebase may also rent clinical providers staff and broaden its attain in Europe.
“We’re additionally positioning for extra advanced varieties of trials. And we’re actually investing closely in a number of the issues that our pharma and biotech clients are in search of,” Lemberg mentioned.
“So we’re actually investing in our digital knowledge seize methods, direct knowledge seize methods, distant monitoring, distant risk-based monitoring, [and] knowledge administration, in order that we will transcend simply that digital expertise and do enterprise-grade knowledge administration for these extra advanced pharmaceutical and biotech research.”
The marketplace for decentralized clinical trial know-how grew during the COVID-19 pandemic, as telehealth and digital care expanded. Different corporations within the area embody THREAD, which earlier this month introduced it had acquired trial recruitment platform CureClick; Reify Well being, which not too long ago raised $220 million in Series D funding; and Medable, which landed more than $300 million in October final yr.
“I believe that earlier than COVID there was already a aim to do what we needed to do. The concept that clinical trials ought to be extra patient-centric, they need to attain sufferers at dwelling of their communities, they need to be sooner, they need to be extra numerous, and that ought to be performed by way of know-how. I believe that is existed for a very long time,” Lemberg mentioned.
“However in fact, there’s danger aversion, and it makes it arduous to implement these issues. I believe COVID actually modified that by making it price taking that probability.”